| Literature DB >> 25371903 |
Soo Tein Ngoi1, Kwai Lin Thong1.
Abstract
The increased Salmonella resistance to quinolones and fluoroquinolones is a public health concern in the Southeast Asian region. The objective of this study is to develop a high resolution melt curve (HRM) assay to rapidly screen for mutations in quinolone-resistant determining region (QRDR) of gyrase and topoisomerase IV genes. DNA sequencing was performed on 62 Salmonella strains to identify mutations in the QRDR of gyrA, gyrB, parC, and parE genes. Mutations were detected in QRDR of gyrA (n = 52; S83F, S83Y, S83I, D87G, D87Y, and D87N) and parE (n = 1; M438I). Salmonella strains with mutations within QRDR of gyrA are generally more resistant to nalidixic acid (MIC 16 > 256 μg/mL). Mutations were uncommon within the QRDR of gyrB, parC, and parE genes. In the HRM assay, mutants can be distinguished from the wild-type strains based on the transition of melt curves, which is more prominent when the profiles are displayed in difference plot. In conclusion, HRM analysis allows for rapid screening for mutations at the QRDRs of gyrase and topoisomerase IV genes in Salmonella. This assay markedly reduced the sequencing effort involved in mutational studies of quinolone-resistance genes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25371903 PMCID: PMC4209765 DOI: 10.1155/2014/718084
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Mutations in the gyrase and topoisomerase IV genes as determined by DNA sequencing and the nalidixic acid minimum inhibitory concentration (MIC) of their corresponding Salmonella strains.
| Strain | MIC ( |
|
|
|
|
|---|---|---|---|---|---|
| SE 109/07 | >256 | D87Y | Silent mutations | None | V521F |
| SE 005/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 022/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 026/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 027/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 028/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 032/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 033/03 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 047/04 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 054/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 064/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 066/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 067/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 069/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 073/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 075/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 078/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 080/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 081/05 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 086/06 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 101/07 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 104/07 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 105/07 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 106/07 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 107/07 | >256 | D87Y | Silent mutations | None | Silent mutations |
| SE 002/03 | 192 | D87Y | Silent mutations | None | Silent mutations |
| SE 076/05 | 192 | D87Y | Silent mutations | None | Silent mutations |
| SE 004/03 | 128 | D87Y | Silent mutations | None | Silent mutations |
| SE 048/04 | 128 | D87Y | Silent mutations | None | Silent mutations |
| SE 097/06 | 128 | D87Y | Silent mutations | None | Silent mutations |
| SE 074/05 | 96 | D87Y | Silent mutations | None | Silent mutations |
| SE 090/06 | 96 | D87Y | Silent mutations | None | Silent mutations |
| SE 068/05 | 64 | D87Y | Silent mutations | None | Silent mutations |
| SE 102/07 | 64 | D87Y | Silent mutations | None | Silent mutations |
| SE 046/04 | 48 | D87Y | Silent mutations | None | Silent mutations |
| SE 049/04 | 48 | D87Y | Silent mutations | None | Silent mutations |
| SE 084/05 | 24 | D87Y | Silent mutations | None | Silent mutations |
| SE 001/03 | 16 | D87Y | Silent mutations | None | Silent mutations |
| SE 065/05 | 16 | D87Y | Silent mutations | None | Silent mutations |
| STM 032/04 | >256 | D87G | None | None | None |
| SE 089/06 | >256 | D87G | Silent mutations | None | Silent mutations |
| SE 095/06 | >256 | D87G | Silent mutations | None | Silent mutations |
| SE 070/05 | 128 | D87G | Silent mutations | None | Silent mutations |
| SE 050/04 | 64 | D87G | Silent mutations | None | Silent mutations |
| SE 012/03 | >256 | D87N | Silent mutations | None | Silent mutations |
| SE 015/03 | >256 | D87N | Silent mutations | None | Silent mutations |
| SE 013/03 | 96 | D87N | Silent mutations | None | Silent mutations |
| STM 043/05 | >256 | S83F | Silent mutations | Silent mutations | Silent mutations |
| SE 055/05 | >256 | S83F | Silent mutations | None | Silent mutations |
| SE 051/04 | >256 | S83I | Silent mutations | None | Silent mutations |
| SE 052/04 | >256 | S83I | Silent mutations | None | Silent mutations |
| SE 099/06 | >256 | S83Y | Silent mutations | None | Silent mutations |
| STM 018/03 | 24 | None | Silent mutations | None | M438I |
| STM 071/07 | 64 | None | Silent mutations | None | None |
| STM 055/05 | 32 | None | Silent mutations | None | None |
| STM 006/02 | 16 | None | Silent mutations | None | None |
| STM 033/04 | 16 | None | Silent mutations | None | None |
| STM 053/05 | 16 | None | Silent mutations | None | None |
| STM 056/05 | 16 | None | Silent mutations | None | None |
| STM 034/04 | 12 | None | Silent mutations | None | None |
| STM 048/05 | 8 | None | Silent mutations | None | None |
| STM 057/05 | 6 | None | None | None | None |
D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; M, methionine; N, asparagine; S, serine; V, valine; Y, tyrosine; “silent mutations” denotes synonymous base substitutions in the QRDR of the target genes and thus does not result in amino acid change; “none” denotes wild-type sequence in the QRDR; that is, base substitution did not take place.
aThe first letter indicates the original amino acid, followed by numbers that indicate the position of the amino acid in respective gene, and the last letter indicates the substituting amino acid. For example, D87Y means tyrosine replaced aspartic acid in position 87 in GyrA subunit.
PCR primer sequences for HRM analysis of gyrase and topoisomerase IV genes.
| Primer | Sequence (5′-3′)b | Amplicon size (bp) |
|---|---|---|
| gyrA-F | CAATGACTGGAACAAAGCCTA | 164 |
| gyrA-R | AACCGAAGTTACCCTGACCA | |
| gyrB-F | TGTCCGAACTGTACCTGGTG | 198 |
| gyrB-R | ACTCGTCGCGACCGATAC | |
| parC-F | CGTCTATGCGATGTCAGAGC | 219 |
| parC-R | ATCGCCGCGAATGACTTC | |
| parE-F | TACCGCGCAGGATCTTAATC | 193 |
| parE-R | GATCGCCACGGAAATATCAT |
bPrimers designed in this study.
Figure 1Representative HRM aligned melting curves (a) and difference plot (b) for mutations in gyrA QRDR. The aligned melting curves were set at 100% at the beginning and 0% at the end of melting process. In the difference plot, the melting curves represent the temperature at which the amplicons were completely denatured. The difference of the melting temperature among the samples is clearly illustrated in the difference plot. The reference strain is indicated by the horizontal black line in the difference plot; and the wild-type samples are indicated as green line. The blue curves derived from mutants with the missense mutation D87G, whereas the red curves belong to other mutants (D87Y, D87N, S83F, and S83Y). Mutants with missense mutations D87Y, D87N, S83F, and S83Y were denatured at similar melting temperature and therefore form a tight cluster.
Figure 2Representative HRM aligned melting curves (a) and difference plot (b) for mutations in gyrB QRDR. The reference strain is indicated by the horizontal black line in the difference plot, while mutants are represented by red (6 mutations within the HRM target region) or blue curves (3 mutations within the HRM target region). All gyrB mutants are silent mutations.
Figure 3Representative HRM aligned melting curves (a) and difference plot (b) for mutations in parC QRDR. The reference strain is indicated by the horizontal black line in difference plot. Wild-type samples are indicated by green curves and the single mutant is indicated by red curve.
Figure 4Representative HRM aligned melting curves (a) and difference plot (b) for mutations in parE QRDR. The reference strain is indicated by the horizontal black line in difference plot. Wild-type samples are indicated by green curves and mutants are indicated by red curves. All mutant strains contain similar nucleotide changes in the QRDR, resulting in tightly clustered melting curves.